Bariatric surgery and the diseased kidney: a 5-year assessment of safety and postoperative renal outcomes.
Chronic kidney disease
Metabolic and bariatric surgery
Renal transplantation
Roux-en-Y gastric bypass
Sleeve gastrectomy
Weight loss
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
13 Jun 2024
13 Jun 2024
Historique:
received:
15
04
2024
accepted:
02
06
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
13
6
2024
Statut:
aheadofprint
Résumé
Obesity and its related medical conditions are well-established contributors to the development of chronic kidney disease (CKD). Metabolic and bariatric surgery (MBS), including procedures such as sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB), is a potential intervention for these individuals. However, the heightened risk of postoperative complications casts doubts on the suitability of MBS in this population. Our aim is to evaluate the long-term safety, anthropometric and renal outcomes of MBS in patients with CKD. A retrospective review of patients who underwent primary laparoscopic MBS with a BMI ≥ 35 kg/m A total of 302 patients (177 SG, 125 RYGB) were included. RYGB was preferred for patients with stage 3 CKD, while SG was more common in stages 4 and 5. At 5-year follow-up, percentage of total weight loss was higher in the RYGB cohort compared to SG (25.1% vs. 18.6%, p = 0.036). Despite SG patients having more advanced CKD, the incidence of late complications was significantly higher following RYGB, with 11 incidents (8.8%), compared to the SG cohort with only 4 cases (2.3%) (p = 0.014). In those with preoperative CKD stage 3, 76 patients (43.2%) improved to stage 2, with another 9 patients (5.1%) improving further to stage 1. Of all patients, 63 (20.8%) eventually received a successful renal transplant. MBS is an effective strategy for sustained weight loss in patients with CKD with acceptable complications rates. RYGB leads to a higher percentage of overall weight loss, albeit with an elevated likelihood of late surgical complications. Future studies are needed to determine the safety of MBS in this demographic.
Sections du résumé
BACKGROUND
BACKGROUND
Obesity and its related medical conditions are well-established contributors to the development of chronic kidney disease (CKD). Metabolic and bariatric surgery (MBS), including procedures such as sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB), is a potential intervention for these individuals. However, the heightened risk of postoperative complications casts doubts on the suitability of MBS in this population. Our aim is to evaluate the long-term safety, anthropometric and renal outcomes of MBS in patients with CKD.
METHODS
METHODS
A retrospective review of patients who underwent primary laparoscopic MBS with a BMI ≥ 35 kg/m
RESULTS
RESULTS
A total of 302 patients (177 SG, 125 RYGB) were included. RYGB was preferred for patients with stage 3 CKD, while SG was more common in stages 4 and 5. At 5-year follow-up, percentage of total weight loss was higher in the RYGB cohort compared to SG (25.1% vs. 18.6%, p = 0.036). Despite SG patients having more advanced CKD, the incidence of late complications was significantly higher following RYGB, with 11 incidents (8.8%), compared to the SG cohort with only 4 cases (2.3%) (p = 0.014). In those with preoperative CKD stage 3, 76 patients (43.2%) improved to stage 2, with another 9 patients (5.1%) improving further to stage 1. Of all patients, 63 (20.8%) eventually received a successful renal transplant.
CONCLUSIONS
CONCLUSIONS
MBS is an effective strategy for sustained weight loss in patients with CKD with acceptable complications rates. RYGB leads to a higher percentage of overall weight loss, albeit with an elevated likelihood of late surgical complications. Future studies are needed to determine the safety of MBS in this demographic.
Identifiants
pubmed: 38872021
doi: 10.1007/s00464-024-10983-9
pii: 10.1007/s00464-024-10983-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Chooi YC, Ding C, Magkos F (2019) The epidemiology of obesity. Metabolism 92:6–10
doi: 10.1016/j.metabol.2018.09.005
pubmed: 30253139
Timothy Garvey W (2019) Clinical definition of overweight and obesity. In: Gonzalez-Campoy JM, Hurley DL, Garvey WT (eds) Bariatric endocrinology: evaluation and management of adiposity, adiposopathy and related diseases. Springer, Cham, pp 121–143
doi: 10.1007/978-3-319-95655-8_7
Lin X, Li H (2021) Obesity: epidemiology, pathophysiology, and therapeutics. Front Endocrinol (Lausanne) 12:706978
doi: 10.3389/fendo.2021.706978
pubmed: 34552557
Sarma S, Sockalingam S, Dash S (2021) Obesity as a multisystem disease: trends in obesity rates and obesity-related complications. Diabetes Obes Metab 23(Suppl 1):3–16
doi: 10.1111/dom.14290
pubmed: 33621415
Webster AC, Nagler EV, Morton RL, Masson P (2017) Chronic kidney disease. Lancet 389(10075):1238–1252
doi: 10.1016/S0140-6736(16)32064-5
pubmed: 27887750
Centers for Disease Control and Prevention (2020) Kidney disease surveillance system. https://nccd.cdc.gov/CKD/TopicHome/PrevalenceIncidence.aspx?topic=1 . Accessed 23 Jan 2024
Xu H, Kuja-Halkola R, Chen X, Magnusson PKE, Svensson P, Carrero JJ (2019) Higher body mass index is associated with incident diabetes and chronic kidney disease independent of genetic confounding. Kidney Int 95(5):1225–1233
doi: 10.1016/j.kint.2018.12.019
pubmed: 30898340
Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS (2006) Body mass index and risk for end-stage renal disease. Ann Intern Med 144(1):21–28
doi: 10.7326/0003-4819-144-1-200601030-00006
pubmed: 16389251
Nguyen S, Hsu CY (2007) Excess weight as a risk factor for kidney failure. Curr Opin Nephrol Hypertens 16(2):71–76
doi: 10.1097/MNH.0b013e32802ef4b6
pubmed: 17293680
Friedman AN, Cohen RV (2019) Bariatric surgery as a renoprotective intervention. Curr Opin Nephrol Hypertens 28(6):537–544
doi: 10.1097/MNH.0000000000000539
pubmed: 31436552
Docherty NG, le Roux CW (2020) Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus. Nat Rev Nephrol 16(12):709–720
doi: 10.1038/s41581-020-0323-4
pubmed: 32778788
Abi Mosleh K, Lind R, Salame M, Jawad MA, Ghanem M, Hage K, Abu Dayyeh BK, Kendrick M, Teixeira AF, Ghanem OM (2023) Comparative multicenter analysis of sleeve gastrectomy, gastric bypass, and duodenal switch in patients with BMI ≥70kg/m(2): a 2-year follow-up. Surg Obes Relat Dis. https://doi.org/10.1016/j.soard.2023.11.011
doi: 10.1016/j.soard.2023.11.011
pubmed: 38182525
Clapp B, Abi Mosleh K, Glasgow AE, Habermann EB, Abu Dayyeh BK, Spaniolas K, Aminian A, Ghanem OM (2023) Bariatric surgery is as safe as other common operations: an analysis of the ACS-NSQIP. Surg Obes Relat Dis. https://doi.org/10.1016/j.soard.2023.11.017
doi: 10.1016/j.soard.2023.11.017
pubmed: 38182525
Clapp B, Janik MR, El Badaoui J, Dodoo C, Portela R, Kellogg T, Ghanem OM (2022) Five-year analysis of the MBSAQIP database: are we getting better? J Am Coll Surg 234(6):1211–1220
doi: 10.1097/XCS.0000000000000177
pubmed: 35703820
Arterburn DE, Telem DA, Kushner RF, Courcoulas AP (2020) Benefits and risks of bariatric surgery in adults: a review. JAMA 324(9):879–887
doi: 10.1001/jama.2020.12567
pubmed: 32870301
Ghusn W, Ikemiya K, Al Annan K, Acosta A, Dayyeh BKA, Lee E, Spaniolas K, Kendrick M, Higa K, Ma P, Ghanem OM (2023) Diabetes mellitus remission in patients with BMI > 50 kg/m(2) after bariatric surgeries: a real-world multi-centered study. Obes Surg 33(6):1838–1845
doi: 10.1007/s11695-023-06622-2
pubmed: 37118640
Ghanem OM, Abi Mosleh K, Kerbage A, Lu L, Hage K, Abu Dayyeh BK (2024) Continued diabetes remission despite weight recurrence: gastric bypass long-term metabolic benefit. J Am Coll Surg 238:862
doi: 10.1097/XCS.0000000000000934
pubmed: 38349010
Cohen JB, Tewksbury CM, Torres Landa S, Williams NN, Dumon KR (2019) National postoperative bariatric surgery outcomes in patients with chronic kidney disease and end-stage kidney disease. Obes Surg 29(3):975–982
doi: 10.1007/s11695-018-3604-2
pubmed: 30443719
pmcid: 6430653
Kukla A, Kudva YC, Navratil P, Sahi SS, Benzo RP, Fipps DC, Erickson AE, Majorowicz RR, Clark MM, Schinstock CA, Shah P, Shah M, Diwan TS (2024) Management of patients with kidney disease undergoing bariatric surgery: a multidisciplinary approach. Mayo Clin Proc 99(3):445–458
doi: 10.1016/j.mayocp.2023.11.008
pubmed: 38432750
Friedman AN, Wahed AS, Wang J, Courcoulas AP, Dakin G, Hinojosa MW, Kimmel PL, Mitchell JE, Pomp A, Pories WJ, Purnell JQ, le Roux C, Spaniolas K, Steffen KJ, Thirlby R, Wolfe B (2018) Effect of bariatric surgery on CKD Risk. J Am Soc Nephrol 29(4):1289–1300
doi: 10.1681/ASN.2017060707
pubmed: 29335242
pmcid: 5875949
Imam TH, Fischer H, Jing B, Burchette R, Henry S, DeRose SF, Coleman KJ (2017) Estimated GFR before and after bariatric surgery in CKD. Am J Kidney Dis 69(3):380–388
doi: 10.1053/j.ajkd.2016.09.020
pubmed: 27927587
Lautenbach A, Wienecke JW, Stoll F, Riedel N, Mann O, Huber TB, Busch P, Aberle J (2021) Bariatric surgery is protective against renal function decline in severely obese patients in the long-term. Obes Surg 31(3):1038–1045
doi: 10.1007/s11695-020-05096-w
pubmed: 33161461
Sheetz KH, Gerhardinger L, Dimick JB, Waits SA (2020) Bariatric surgery and long-term survival in patients with obesity and end-stage kidney disease. JAMA Surg 155(7):581–588
doi: 10.1001/jamasurg.2020.0829
pubmed: 32459318
pmcid: 7254435
Kidney Disease Improving Global Outcomes (KDIGO) (2016) CKD evaluation and management. https://kdigo.org/guidelines/ckd-evaluation-and-management/ . Accessed 26 Jan 2024
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15273542
pmcid: 1360123
Prasad R, Jha RK, Keerti A (2022) Chronic kidney disease: its relationship with obesity. Cureus 14(10):e30535
pubmed: 36415443
pmcid: 9675899
Abou-Mrad RM, Abu-Alfa AK, Ziyadeh FN (2013) Effects of weight reduction regimens and bariatric surgery on chronic kidney disease in obese patients. Am J Physiol Renal Physiol 305(5):F613–F617
doi: 10.1152/ajprenal.00173.2013
pubmed: 23825072
Verde L, Lucà S, Cernea S, Sulu C, Yumuk VD, Jenssen TG, Savastano S, Sarno G, Colao A, Barrea L, Muscogiuri G (2023) The fat kidney. Curr Obes Rep 12(2):86–98
doi: 10.1007/s13679-023-00500-9
pubmed: 36933154
pmcid: 10250266
Sharma I, Nakanishi H, Hage K, Marrero K, Diwan TS, daSilva-deAbreu A, Davis SS Jr, Clapp B, Ghanem OM (2023) Bariatric surgery and left ventricular assist device in patients with heart failure: a systematic review and meta-analysis. Am J Surg 226(3):340–349
doi: 10.1016/j.amjsurg.2023.06.014
pubmed: 37355375
Turgeon NA, Perez S, Mondestin M, Davis SS, Lin E, Tata S, Kirk AD, Larsen CP, Pearson TC, Sweeney JF (2012) The impact of renal function on outcomes of bariatric surgery. J Am Soc Nephrol 23(5):885–894
doi: 10.1681/ASN.2011050476
pubmed: 22383694
Khajeh E, Aminizadeh E, Dooghaie Moghadam A, Sabetkish N, Abbasi Dezfouli S, Morath C, Zeier M, Nickel F, Billeter AT, Müller-Stich BP, Mehrabi A (2023) Bariatric surgery in patients with obesity and end-stage renal disease. Surg Obes Relat Dis 19(8):858–871
doi: 10.1016/j.soard.2023.01.015
pubmed: 36801168
Chang AR, Grams ME, Navaneethan SD (2017) Bariatric surgery and kidney-related outcomes. Kidney Int Rep 2(2):261–270
doi: 10.1016/j.ekir.2017.01.010
pubmed: 28439568
pmcid: 5399773
Pucci A, Batterham RL (2019) Mechanisms underlying the weight loss effects of RYGB and SG: similar, yet different. J Endocrinol Invest 42(2):117–128
doi: 10.1007/s40618-018-0892-2
pubmed: 29730732
Pereira J, Pereira PR, Andrade S, Pereira SS, Nora M, Guimarães M, Monteiro MP (2023) The impact of early-stage chronic kidney disease on weight loss outcomes after gastric bypass. Obes Surg 33(12):3767–3777
doi: 10.1007/s11695-023-06862-2
pubmed: 37816974
pmcid: 10687110
Winckelmann LA, Gribsholt SB, Madsen LR, Richelsen B, Svensson E, Jørgensen NB, Kristiansen VB, Pedersen SB (2022) Roux-en-Y gastric bypass versus sleeve gastrectomy: nationwide data from the Danish quality registry for treatment of severe obesity. Surg Obes Relat Dis 18(4):511–519
doi: 10.1016/j.soard.2021.12.015
pubmed: 35082100
Clapp B, Marrero K, Corbett J, Sharma I, Hage K, Vierkant RA, McKenzie T, Davis SS Jr, Ghanem OM (2023) Effect of operative times in bariatric surgery on outcomes: a matched analysis of the MBSAQIP database. Surg Endosc 37(6):4113–4122
doi: 10.1007/s00464-023-09927-6
pubmed: 36752855
Al-Bahri S, Fakhry TK, Gonzalvo JP, Murr MM (2017) Bariatric surgery as a bridge to renal transplantation in patients with end-stage renal disease. Obes Surg 27(11):2951–2955
doi: 10.1007/s11695-017-2722-6
pubmed: 28500419
Maroun J, Vahibe A, Shah M, Mundi MS, Acosta A, McKenzie TJ, Kellogg TA, Ghanem OM (2023) Impact of chronic immunosuppression on short-, mid-, and long-term bariatric surgery outcomes. Obes Surg 33(1):240–246
doi: 10.1007/s11695-022-06372-7
pubmed: 36469206
Prochaska M, Worcester E (2020) Risk factors for kidney stone formation following bariatric surgery. Kidney360 1(12):1456–1461
doi: 10.34067/KID.0004982020
pubmed: 34085046
pmcid: 8171111
Singhal R, Cardoso VR, Wiggins T, Super J, Ludwig C, Gkoutos GV, Mahawar K (2022) 30-day morbidity and mortality of sleeve gastrectomy, Roux-en-Y gastric bypass and one anastomosis gastric bypass: a propensity score-matched analysis of the GENEVA data. Int J Obes (Lond) 46(4):750–757
doi: 10.1038/s41366-021-01048-1
pubmed: 34912046
Chahal-Kummen M, Salte OBK, Hewitt S, Blom-Høgestøl IK, Risstad H, Kristinsson J, Mala T (2020) Health benefits and risks during 10 years after Roux-en-Y gastric bypass. Surg Endosc 34(12):5368–5376
doi: 10.1007/s00464-019-07328-2
pubmed: 31993812
pmcid: 7644522